Compare TORM plc (TRMD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TORM plc vs State Street SPDR S&P Biotech ETF — how do they compare? TORM plc trades at $33.16 (market cap $3.58B), while State Street SPDR S&P Biotech ETF trades at $159.9. The key difference: TORM plc pays a 12.65% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| TRMD | XBI | |
|---|---|---|
Market Cap | $3.58B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $35.46 | $169.55 |
52-Week Low | $19.39 | $93.43 |
Enterprise Value | $4.28B | — |
Dividend Yield | 12.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TRMD trades at $34.94, down 0.68% today, with a bullish technical signal from moving averages and strong support at $34. The company reported record Q2 2026 earnings with $3.25 EPS, though slightly missing estimates, and maintains robust profitability with a 35.52% net margin. Recent news highlights a capital increase from RSU exercises and a strong dividend of $2.40 payable in September 2026.
Outlook is positive with 100% analyst buy ratings, underpinned by strong cash flow growth and high ROE of 26.84%. Risks include reliance on volatile freight rates and potential market corrections given elevated RSI levels. The stock presents value with a low P/E of 5.75, but investors should monitor earnings consistency and global trade dynamics.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
